OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right


OriGene Antibodies in recent publications
Role of Glutamine Transaminases in Nitrogen, Sulfur, Selenium, and 1-Carbon Metabolism Glutamine in Clinical NutritionNutrition and Health Nov 2014 [NIT2]

Overexpression of CX3CR1 is associated with cellular metastasis, proliferation and survival in gastric cancer Oncol. Rep. Feb 2015 [CX3CR1]

PRRX1 promotes epithelial-mesenchymal transition through the Wnt/ß-catenin pathway in gastric cancer Med. Oncol. Jan 2015 [PRRX1]

Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins ONCOLOGY LETTERS Jan 2015 [GAPDH]

View All Citations >>
Home Gene of the month ERG

ERG Is A Prostate Cancer Biomarker

divider

The TMPRSS2-ERG gene rearrangements are commonly present in prostate cancer. Over-expression of ERG has also been considered as a specific prostate cancer biomarker which is rarely found in other cancers or normal tissues. Compared against current prostate cancer biomarkers, such as serum PSA level, which are often inadequate to accurately predict disease progression, early detection of TMPRSS2-ERG fusion gene, or simply detection of ERG over-expression would provide a significant diagnostic and prognostic value. See reference publication below.

Current methods to detecting TMPRSS2-ERG gene fusion include FISH assay, sequencing, qPCR assay and IHC. OriGene has developed a powerful tool for detecting ERG over-expression using TissueScan™ Tissue cDNA Arrays which contain panels of first strand cDNAs converted from RNA from cancer and normal tissues. This unique qPCR platform allows gene expression survey in hundreds’ cancer tissues within hours. Using our Cancer Survey cDNA Array (Cat# CSRT102) which contains 384 different samples of different cancer types including prostate cancer, our results demonstrate that only prostate cancer (40% of total tested prostate cancer samples) but not other cancer types or normal tissues shows up to 50-fold increase of ERG expression (see attached Fig.), supporting ERG overexpression is a prostate cancer specific phenomenon and could be provided as a specific marker for identifying aggressive prostate cancer subtype and guiding for proper treatment.

QPCR-prostate2

Citation:

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. By MA Rubin et al. Oncogene (2007) 26, 4596–4599.

OriGene Products for ERG:

  1. TissueScan Tissue cDNA Arrays for gene expression in prostate and other cancer tissues
  2. ERG gene specific full-length cDNA clones, recombinant proteins, shRNA, and antibodies

 

patterns
Inc 5000 Healthcare Company Copyright © 2015 OriGene Technologies, Inc. All Rights Reserved. Legal Notices.
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 • 1.888.267.4436

Reproduction of any materials from this website is strictly forbidden without permission.

All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title